Organon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Book value per share
Organon & Co.'s book value per share at the end of fiscal 2025 was 2.9×, up 57.8% from 1.8× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 4.5×. Over the past ten years it has ranged from −5.9× (fiscal 2021) to 27.7× (fiscal 2019); the current reading is higher than 78% of that period. Organon & Co. ranks 15th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 2.9× | 57.82% |
| FY2024 | 1.8× | — |
| FY2023 | −0.3× | — |
| FY2022 | −3.5× | — |
| FY2021 | −5.9× | — |
| FY2020 | 21.6× | (22.02%) |
| FY2019 | 27.7× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 4.5× | 18.59% |
| Jun 2026 | 3.8× | 10.46% |
| Mar 2026 | 3.5× | 19.68% |
| Dec 2025 | 2.9× | (16.85%) |
| 25 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BIIB Biogen Inc. compare | 128× |
| SNY Sanofi compare | 35.1× |
| AMRN Amarin Corporation PLC compare | 21.3× |
| PFE Pfizer Inc. compare | 15.7× |
| GSK GSK PLC Sponsored ADR compare | 12.3× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| NVO Novo Nordisk A/S compare | 7.6× |
| OGN Organon & Co. | 4.5× |
| GRFS Grifols, S.A. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement